For instance, Gao and colleagues showed that the promoter hypermethylation of Claudin 11 (CLDN11) can be used to discriminate between CM and dysplastic nevi, thus representing a potential melanoma-specific epigenetic biomarker [43]. This evidence concerns the gene CLDN11 and dysplastic nevus.